GSM Treatments Compared: Moisturizers, Local Hormones, Ospemifene, and Devices

What you are comparing

Genitourinary syndrome of menopause (GSM) is the cluster of vaginal dryness, irritation, pain with sex, and urinary symptoms that can follow estrogen loss. The National Institute on Aging describes menopause-related genital changes as common and treatable. This comparison is about first-line comfort care, prescription local hormones, an oral tablet, and energy devices, not about finding a clinic that promises to reverse aging.

Moisturizers and lubricants are nonhormonal. Moisturizers are used on a schedule to reduce dryness. Lubricants are used at the time of sexual activity. They do not treat estrogen deficiency in tissue the way a hormone product can, but they often reduce friction and discomfort enough that no prescription is needed.

Local vaginal estrogen and vaginal DHEA (prasterone) are prescription therapies designed to act mainly in vaginal tissue. Ospemifene is an oral selective estrogen receptor modulator approved for moderate to severe dyspareunia and vaginal dryness due to menopause. It has systemic exposure and a boxed warning about endometrial and cardiovascular risks.

Lasers and other energy devices are offered in many sexual-wellness and aesthetic clinics for GSM-like symptoms. They are procedures, not FDA-approved hormone alternatives with the same evidence base. NAMS and other reviews have found insufficient high-quality placebo-controlled data to treat them as standard care. You are comparing evidence strength and systemic exposure, not prestige.

How they differ

Evidence is uneven. Regular moisturizers and lubricants have practical support for mild symptoms and almost no hormone exposure. Low-dose vaginal estrogen has the longest clinical track record for GSM. Vaginal DHEA also has trial data for dyspareunia. Ospemifene has randomized evidence for dryness and pain with sex. Device studies are often small, industry-linked, or poorly sham-controlled.

Systemic exposure differs. Lubricants and moisturizers are topical comfort products. Low-dose vaginal estrogen typically produces much lower blood levels than systemic menopausal hormone therapy, though it is not a zero-absorption product. Vaginal DHEA is converted locally to sex steroids. Ospemifene is taken by mouth and acts throughout the body, including the endometrium.

Contraindications and monitoring differ with that exposure. Unexplained postmenopausal bleeding needs evaluation before any estrogen-agonist therapy. Ospemifene labeling warns about endometrial cancer, stroke, and deep-vein thrombosis and is contraindicated in certain hormone-sensitive cancers and in pregnancy. Local estrogen decisions in breast-cancer survivors belong with gynecology and oncology, not a device salesperson.

Burden and cost also differ. Moisturizers are over-the-counter and ongoing. Vaginal hormones are usually used several times a week after an induction phase. Ospemifene is a daily tablet and may cause hot flashes. Devices are cash-pay series with maintenance sessions. Compounded vaginal hormones add dosing uncertainty; professional groups often prefer FDA-regulated products when a hormone is appropriate.

Who each option is for

Moisturizers and lubricants are a reasonable first step for mild dryness or pain with sex, including people who want to avoid hormones or who are still completing a diagnostic visit. They also remain useful as add-ons when a prescription is started. Choose products without irritating fragrances if tissue is already sore.

Local vaginal estrogen or vaginal DHEA may fit moderate to severe GSM after a clinician confirms the diagnosis and reviews bleeding, pelvic pain, and infection. These options are often preferred when urinary frequency or recurrent discomfort accompanies atrophy and nonhormonal care is not enough. They are not automatic substitutes for systemic hormone therapy when hot flashes are the main complaint.

Ospemifene may fit someone with bothersome dryness or dyspareunia who cannot insert a vaginal product, or who prefers a tablet, and who has no contraindication after a full history. It is a poor first choice if the only problem is mild dryness that a moisturizer could address, or if stroke, clot, or unexplained bleeding risk has not been reviewed.

Devices are, at most, a later option after better-supported care, and only with a specialist who explains limits, repeat cost, and uncommon burns or scarring. They are a poor first purchase for untreated GSM and a poor standalone plan if you have post-menopausal bleeding, a pelvic mass, or pain that could be another diagnosis.

Risks of choosing the wrong one

Staying only on a lubricant when tissue is severely atrophic can leave pain, microtears, and sexual avoidance in place. That is undertreatment, not caution. The opposite error is starting a systemic or local hormone, or a device series, before anyone examines the vulva or asks about bleeding, discharge, or a history of cancer.

Using ospemifene as if it were a lubricant ignores systemic risk. Hot flashes, clotting and stroke warnings, and the need to evaluate persistent bleeding are part of the drug, not fine print. Combining estrogen-agonist therapies without a plan can raise exposure without adding benefit.

Choosing a laser because it is marketed as hormone-free can delay effective therapy and spend money on a weaker evidence base. Some patients have had tissue injury. A device that requires you to stop asking about FDA-approved options is a sales funnel. Energy treatment also does not evaluate pelvic-floor muscle pain, which may need physical therapy instead.

People with breast cancer, undiagnosed bleeding, or estrogen-sensitive disease face extra harm if a clinic treats GSM as a spa add-on. Shared decision-making with the treating oncologist is the safety step. A practitioner who will not coordinate, or who sells compounded high-dose vaginal estrogen without monitoring, is the wrong person for this problem.

How to decide

Start with a licensed clinician who will examine you and name the diagnosis. GSM is common after menopause, but lichen sclerosus, infection, pelvic-floor myalgia, and dermatologic disease can look similar. Ask what will be tried first and what finding would change the plan, including referral to gynecology or pelvic-floor physical therapy.

Use nonhormonal moisturizers and lubricants while you complete that visit, unless you have already failed them. If symptoms remain bothersome, ask about low-dose vaginal estrogen or vaginal DHEA, including how little systemic exposure is expected and what bleeding should trigger a call. Bring your cancer and clot history in writing.

Consider ospemifene only after you understand it is systemic. Read the boxed warning with the prescriber. Ask how endometrium and cardiovascular risk will be handled and whether a vaginal product was appropriately offered first. Do not start it from an online protocol that never examined you.

Treat devices as optional and later. Ask for sham-controlled evidence, expected duration of benefit, maintenance cost, and injury rates. If the answer is a before-and-after photo, decline. Keep sexual-wellness goals tied to comfort and function, not to a claim that a machine restores youth. Reassess in 8 to 12 weeks with the same symptom questions you started with.